What is the impact of antibiotic resistance?

Antibiotic resistance leads to untreatable infections, causing millions of deaths.

How do pharmaceutical companies prioritize drug development?

Pharmaceutical companies prioritize profitable drugs over antibiotics due to economic concerns.

Hospitals struggle with containing superbugs like KPC, leading to outbreaks.

Antibiotic resistance limits treatment options, posing a significant challenge.

The U.S. government has a national plan emphasizing surveillance and collaboration.

Antibiotic-resistant bacteria are a global threat, causing millions of infections and thousands of deaths yearly, with overuse contributing to the emergence of untreatable strains.
Pharmaceutical companies, like Pfizer, face economic challenges in developing new antibiotics due to high costs and prioritize other medications for profitability, leading to limited investment in combating antibiotic resistance despite its growing threat.

What is the impact of antibiotic resistance?
Antibiotic resistance leads to untreatable infections, causing millions of deaths.
How do pharmaceutical companies prioritize drug development?
Pharmaceutical companies prioritize profitable drugs over antibiotics due to economic concerns.
What challenges do hospitals face with superbugs?
Hospitals struggle with containing superbugs like KPC, leading to outbreaks.
How does antibiotic resistance affect medical treatment?
Antibiotic resistance limits treatment options, posing a significant challenge.
What initiatives are in place to combat antibiotic resistance?
The U.S. government has a national plan emphasizing surveillance and collaboration.

00:00

Globally, untreatable bacteria are emerging, causing at least 2 million infections annually, resulting in 23,000 deaths.
Overuse of antibiotics has led to a shortage, with new threats arising from unknown sources.
Antibiotics are recognized as problematic in a purely capitalist market, requiring resources for solutions.
Addie, an 11-year-old girl from Tucson, Arizona, fell critically ill with a staph infection leading to pneumonia.
Addie's condition deteriorated rapidly, requiring life support and facing antibiotic-resistant bacteria.
Addie's infection became pan-resistant, exhausting medical options, leading to a decision to surgically remove the infection.
David Ricci, a 19-year-old American in India, suffered a severe leg injury, leading to multiple surgeries and infections.
Ricci unknowingly brought the NDM-1 superbug to the US, a highly resistant gene found in various bacteria.
NDM-1's ability to transfer between bacteria in the environment poses a significant risk, spreading rapidly.
Ricci's case in Seattle highlighted the challenges of treating drug-resistant bacteria, with limited clinical knowledge available.

19:30

Doctors arrived at the door, informing the need for isolation and quarantine due to a resistant gene spreading in Ricci's leg.
Five bugs were resistant to antibiotics, leading to concern about treatment options.
Lynch tried various antibiotics unsuccessfully, resorting to a 1940s antibiotic, colistin, due to limited options.
Colistin's toxicity posed challenges, causing organ damage and necessitating treatment cessation.
Despite efforts, no effective antibiotic remained to treat the resistant infections in Ricci's leg.
Hospitals in New York faced a homegrown superbug, KPC, spreading resistance within the digestive system.
The NIH tackled a KPC outbreak by implementing strict isolation measures and infection control protocols.
Despite initial containment success, KPC spread to other patients, leading to a hospital-wide outbreak.
Genetic research revealed silent carriers transmitting KPC unknowingly, complicating containment efforts.
The threat of antibiotic resistance, exemplified by the emergence of CG307, poses a significant challenge to modern medicine's reliance on antibiotics.

38:24

Developing a new antibiotic can cost between $600 million and $1 billion, making it economically challenging for developers.
Large pharmaceutical companies often prioritize investing in drugs like cholesterol, blood pressure, and arthritis medications over antibiotics due to profitability concerns.
Pfizer faced a crisis in 2011 when its stock plummeted, leading to the closure of its antibiotic development facility after 70 years of leadership.
In 2013, Pfizer defended its shift from antibiotic research to vaccines as necessary portfolio decisions to meet medical needs and investor expectations.
Despite re-entering the antibiotic market in 2016, Pfizer, like other pharmaceuticals, still lacks significant investment in antibiotic research.
The U.S. government, under the Obama administration, initiated a national plan in 2015 to combat antibiotic-resistant bacteria, emphasizing surveillance, stewardship, and international collaboration.
Concerns over antibiotic resistance are growing, with predictions that superbugs could kill 10 million people annually by 2050, highlighting the urgent need for increased investment and regulation in antibiotic development and usage.